Jefferies Financial Group Inc. Boosts Stock Position in Embecta Corp. $EMBC

Jefferies Financial Group Inc. raised its holdings in Embecta Corp. (NASDAQ:EMBC) by 40.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,884,875 shares of the company’s stock after purchasing an additional 542,162 shares during the quarter. Jefferies Financial Group Inc. owned 3.22% of Embecta worth $26,596,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Laurel Wealth Advisors LLC boosted its holdings in shares of Embecta by 754.3% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,871 shares of the company’s stock worth $193,000 after buying an additional 1,652 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after buying an additional 6,224 shares during the last quarter. Neuberger Berman Group LLC purchased a new stake in Embecta during the third quarter worth about $143,000. Pacer Advisors Inc. bought a new stake in Embecta in the third quarter worth about $156,000. Finally, Summit Global Investments bought a new stake in Embecta in the third quarter worth about $161,000. 93.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on EMBC shares. BTIG Research reissued a “buy” rating and set a $25.00 target price on shares of Embecta in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $18.50.

Embecta Stock Performance

Shares of Embecta stock opened at $9.07 on Monday. Embecta Corp. has a 52-week low of $9.06 and a 52-week high of $15.55. The stock’s 50-day simple moving average is $11.08 and its 200 day simple moving average is $12.74. The stock has a market capitalization of $537.13 million, a P/E ratio of 3.83 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.67 by $0.04. The business had revenue of $261.20 million for the quarter, compared to the consensus estimate of $258.07 million. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company’s revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Equities research analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 17th. Investors of record on Friday, February 27th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date is Friday, February 27th. Embecta’s dividend payout ratio is presently 25.32%.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.